MAPK signalling pathway is a downstream target of Ras family members and activating KRAS mutations are one of the main features underlying CC development and resistance to therapy.15 Importantly, activation of MEK5 has recently been associated with decreased overall survival of CC patients.16 Collectively, MEK5/ERK5 overexpression or increased activation in several human cancers and its association with a poorer disease survival makes ERK5 a potential desirable target for the development of additional novel cancer therapies. Here, KRAS is linked to cancer.